Levetiracetam in children with refractory status epilepticus
Levetiracetam in children with refractory status epilepticus
复制标题
DOI：
10.1016/j.yebeh.2008.09.028
复制
发表时间：
2009-01-01
影响因子：
2.6
通讯作者：
Husain, Aatif M.
中科院分区：
文献类型：
--
作者：
Gallentine, William B.;Hunnicutt, Addie S.;Husain, Aatif M.
本研究的目的是探讨左乙拉西坦(Lev)在儿童难治性癫痫持续状态(RSE)中的应用。我们回顾了接受LEV辅助治疗的RSE儿童的记录。在7年的时间里，I儿童接受了RSE的LEV。年龄2天~9岁(中位数2.5个月)。在接受LEV治疗之前，用于治疗RSE的抗惊厥药物的数量从2到7(中位数=3)。起始量为15~70 mg/kg(中位数为30 mg/kg)。45%(5/11)的患者认为LEV是有益的，结果要么RSE得到缓解，要么患者成功地脱离了持续输注其他抗惊厥药物。在27%(3/11)中，对LEV的反应不清楚，因为在使用LEV的同时添加或增加了其他药物。LEV启动后RSE停止的中位潜伏期为1.5天(范围为1-8天)。所有有反应的患者都服用Lev剂量=30 mg/kg/d(中位数40 mg/kg/d)。没有关于LEV的显著不良反应的报道。LEV可能是治疗儿童RSE的一种安全有效的辅助治疗方法。(C)2008 Elsevier Inc.保留所有权利。
The objective of this Study was to investigate the utility of levetiracetam (LEV) in children with refractory status epilepticus (RSE). Records of children with RSE who received LEV as adjunctive therapy were reviewed. Over a 7-year period, I I children had received LEV for RSE. Age ranged from 2 days to 9 years (median = 2.5 months). Prior to administration of LEV, the number of anticonvulsants used to treat RSE ranged from 2 to 7 (median = 3). Starting doses of LEV ranged from 15 to 70 mg/kg (median = 30 mg/kg). LEV was felt to be of benefit in 45% (5/11) of cases, resulting in either resolution of RSE or successful weaning of patients Off Continuous infusions of other anticonvulsants. In 27% (3/11), response to LEV was unclear as other medications were either added or increased concomitantly with LEV use. The median latency to cessation of RSE following LEV initiation was 1.5 days (range = 1-8 days). All responding patients were on LEV doses >= 30 mg/kg/day (median 40 mg/kg/day). No significant adverse effects of LEV were reported. LEV may be an effective and safe adjuvant therapy in children with RSE. (c) 2008 Elsevier Inc. All rights reserved.